MedMira Inc. MIR
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow MedMira Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
TSX-V
Type
Biotech
Sector
Rapid diagnostic technology
Price & valuation
Last close
CAD 0.07
1 week
+8.3 %
3 months
+8.3 %
12 months
-18.8 %
From 52w high
-35.0 %
From 52w low
+8.3 %
We're already tracking MedMira Inc. — here are the latest events we've registered
Recent News
- On April 1, 2026, MedMira reported its second-quarter financial results and announced a new distribution agreement with McKesson to expand its market reach in North America. The company also highlighted progress in clinical trials for its Multiplo Complete Syphilis test and its Multiplo TP/HIV self-test in Canada. These developments are part of the company's strategy to increase access to rapid screening solutions.
What Firelda Watch includes for MedMira Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of MedMira Inc. will be delivered in the same format.
Want to follow MedMira Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.